Evidence map›Paper›PMID 23402636›Full record

ReviewJournal of medicinal food2013

Health benefits of blue-green algae: prevention of cardiovascular disease and nonalcoholic fatty liver disease.

Chai Siah Ku, Yue Yang, Youngki Park, Jiyoung Lee

Abstract readReview
In one paragraph

Review in Journal of medicinal food, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 115 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Antioxidant Efficacy of aMarine drugs · 2022
    Trial
  4. Trial
  5. Molecules (Basel, Switzerland) · 2026
    Review
  6. Anticancer and Antimicrobial Activity ofMolecules (Basel, Switzerland) · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Supplementation withMarine drugs · 2022
    Article
  14. Article
  15. Article
  16. Protective impact ofToxicology research · 2021
    Article
  17. Review
  18. Article
  19. Review
  20. AphaMaxNutrients · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Chai Siah KuDepartment of Nutritional Sciences, University of Connecticut, Storrs, Connecticut, USA.
Yue Yang
Youngki Park
Jiyoung Lee
University of Connecticut · US

Funding

Evaluation of athero-protective role of blue-green algaeR21AT005152 · NCCIH · UNIVERSITY OF NEBRASKA LINCOLN · PI LEE, JI-YOUNG · 2009 to 2010
$387k
NCCIH NIH HHS R21AT005152
6 · The paper itself

Abstract

Blue-green algae (BGA) are among the most primitive life forms on earth and have been consumed as food or medicine by humans for centuries. BGA contain various bioactive components, such as phycocyanin, carotenoids, γ-linolenic acid, fibers, and plant sterols, which can promote optimal health in humans. Studies have demonstrated that several BGA species or their active components have plasma total cholesterol and triglyceride-lowering properties due to their modulation of intestinal cholesterol absorption and hepatic lipogenic gene expression. BGA can also reduce inflammation by inhibiting the nuclear factor κ B activity, consequently reducing the production of proinflammatory cytokines. Furthermore, BGA inhibit lipid peroxidation and have free radical scavenging activity, which can be beneficial for the protection against oxidative stress. The aforementioned effects of BGA can contribute to the prevention of metabolic and inflammatory diseases. This review provides an overview of the current knowledge of the health-promoting functions of BGA against cardiovascular disease and nonalcoholic fatty liver disease, which are major health threats in the developed countries.

Indexed as

AnimalsCardiovascular DiseasesCyanobacteriaDeveloped CountriesFatty LiverFunctional FoodHumansNon-alcoholic Fatty Liver Disease

Identifiers

PMID23402636
PMCPMC3576896
OpenAlexW2121123155

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.